In September 2025, the only FDA-approved tesamorelin product in the world quietly changed its label dose. The old Egrifta dose was 2 mg once daily. Egrifta WR, the formulation that has now replaced it, is dosed at 1.28 mg once daily — and regulators accepted that the two deliver the same drug exposure. Nothing about the molecule changed. What changed was the concentration in the vial, the injection volume, and how long the reconstituted solution survives on a bench.

That detail matters far beyond one HIV product line, because it exposes something most tesamorelin research summaries skip: with this peptide, a milligram number on a label is close to meaningless unless you also know the formulation it belongs to. If you are trying to make sense of tesamorelin australia discussions, mg-per-day comparisons are the wrong unit to argue about. Here is the pharmacology behind that.

What is tesamorelin, and why is the dose so formulation-dependent?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It acts on the pituitary to stimulate pulsatile growth hormone release, which in turn raises IGF-1. It has been FDA-approved since 2010 — under the brand Egrifta — for one narrow indication: reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It has never been approved in Europe; the European application was withdrawn before approval in 2012. Background on the compound sits on our tesamorelin profile.

Two numbers from the FDA label explain the formulation sensitivity.

First, absolute bioavailability after subcutaneous injection of a 2 mg dose was determined to be less than 4% in healthy adults. Over 96% of the injected peptide never reaches systemic circulation intact.

Second, tesamorelin disappears fast. The label reports a mean elimination half-life of roughly 26 minutes for the original 1 mg/vial formulation after 14 days of dosing, and about 8 minutes after a single dose of the more concentrated 2 mg/vial formulation in healthy volunteers.

When a drug has single-digit-percent bioavailability and a half-life measured in minutes, the fraction absorbed is highly sensitive to what surrounds the peptide — concentration, excipients, injected volume, depot geometry. Change those, and the same nominal milligram dose can produce quite different exposure. That is exactly why the manufacturer had to run a dedicated pharmacokinetic bridging study rather than simply keep the 2 mg number.

The bioequivalence data behind 1.28 mg

Egrifta WR uses what the manufacturer calls the F8 formulation: an 11.6 mg vial that is reconstituted once and then provides seven consecutive daily doses of 1.28 mg in just 0.16 mL, with the reconstituted solution stable at room temperature for up to seven days. Trade press reporting describes F8 as roughly eight times the concentration of the original Egrifta formulation and about twice that of Egrifta SV.

The approval rested on pharmacokinetic bioequivalence, not on a new efficacy trial. A sponsor-authored abstract presented as poster P-1230 and published in an Open Forum Infectious Diseases conference supplement describes a single-centre, randomised, blinded, two-period crossover study in 36 healthy adults given single doses. The geometric least-squares mean ratios were 108.0% for Cmax and 96.9% for AUC0-t, with 90% confidence intervals inside the conventional 80–125% acceptance window.

Worth stating plainly: that is a small, single-dose study in healthy volunteers, not people with HIV-associated lipodystrophy, and the primary public description is a conference abstract from the sponsor rather than a full peer-reviewed pharmacokinetic paper. It is a regulatory bridging exercise. It carries no new information about whether tesamorelin works, only about how much drug gets in.

The commercial backdrop also shifted. Egrifta SV supply was disrupted in early 2025 after a contract manufacturer's facility was voluntarily shut down following an unfavourable FDA inspection; WR, manufactured in the US, became available later that year. Theratechnologies itself was acquired by Future Pak, completing in September 2025.

Why the seven-day room-temperature detail is the real change

For an approved product, weekly reconstitution and room-temperature stability are convenience and adherence features. Read the other way, they are a reminder of what the original formulations were not: tesamorelin is a peptide that historically needed careful cold handling and fresh preparation. Reformulating it to survive a week at room temperature took a dedicated development programme, a patent estate and a bridging PK study. It is not something achieved by choosing a different diluent.

Is tesamorelin legal in Australia? The regulatory position

Is tesamorelin legal in australia is one of the most common searches on this compound, and the answer is unambiguous on the supply side: no tesamorelin product is on the Australian Register of Therapeutic Goods. Neither Egrifta, Egrifta SV nor Egrifta WR is an approved Australian medicine. Any access would be through unapproved-goods pathways at a prescriber's initiative, not an ordinary script for a registered product.

That has a specific consequence for the dosing question above. Because there is no Australian-approved tesamorelin, there is no Australian label dose — and no Australian formulation to which any "mg per day" figure circulating online is anchored. A research-labelled vial marked 2 mg is not the Egrifta 2 mg dose, and not 1.28 mg of Egrifta WR either, because the number describes vial content, not verified delivered exposure. Independent testing of grey-market growth hormone products has repeatedly found content that does not match labels, which compounds the problem.

For athletes, GHRH analogues including tesamorelin sit in WADA's S2 category (peptide hormones, growth factors, related substances and mimetics) and are prohibited at all times.

Comparable formulation and exposure questions run across the wider category — see our peptides section — and you can join the free updates list for future tesamorelin coverage.

FAQ

What is the dose of tesamorelin?

The only approved dosing is for HIV-associated lipodystrophy. The original Egrifta dose was 2 mg once daily subcutaneously; Egrifta WR, the current US formulation, is 1.28 mg once daily in 0.16 mL, accepted as bioequivalent on pharmacokinetic grounds.

Why is tesamorelin's bioavailability so low?

The FDA label reports absolute bioavailability of under 4% after a 2 mg subcutaneous dose, with an elimination half-life of roughly 8–26 minutes depending on formulation and dosing. It is a rapidly cleared peptide, which is why formulation changes require bridging pharmacokinetic studies.

Is tesamorelin legal in Australia?

No tesamorelin product is on the ARTG, so there is no approved Australian medicine. It is FDA-approved in the US for HIV-associated lipodystrophy only, was never approved in Europe, and is prohibited in sport by WADA.

Is Egrifta WR a new drug?

No. It is the same molecule in a more concentrated formulation allowing weekly reconstitution and up to seven days of room-temperature storage. Approval was based on pharmacokinetic bioequivalence, not a new efficacy trial.

Sources

Not medical advice. retatrutide.net.au is independent and does not sell or source any compound. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy, was never approved in Europe, and is not on the ARTG.